Interferon-gamma (IFN-γ) testing is a critical immunological assay used to evaluate cell-mediated immune responses, diagnose tuberculosis infection, and assess immune dysfunction. This comprehensive guide covers the technical principles, sample types, detection methods, and clinical applications of IFN-γ measurement in modern laboratory diagnostics.
Technical Overview
Interferon-gamma (IFN-γ), also known as type II interferon, is a dimeric glycoprotein cytokine produced primarily by T lymphocytes (CD4+ Th1 cells and CD8+ cytotoxic T cells) and natural killer (NK) cells upon antigenic stimulation. It plays a central role in cell-mediated immunity, macrophage activation, antigen presentation, and the host defense against intracellular pathogens such as Mycobacterium tuberculosis. The quantitative or qualitative measurement of IFN-γ release has become an essential tool in clinical immunology, infectious disease diagnostics, and immunopharmacology research.
IFN-γ determination encompasses several analytical approaches, including enzyme-linked immunosorbent assay (ELISA), enzyme-linked immunospot (ELISpot) assay, flow cytometric intracellular cytokine staining, and biological activity assays. The choice of method depends on the intended application: serological quantification of secreted IFN-γ, enumeration of IFN-γ-secreting cells at the single-cell level, or functional assessment of immune cell populations. Among clinical applications, interferon-gamma release assays (IGRAs) have gained widespread adoption for the diagnosis of latent tuberculosis infection (LTBI), replacing or complementing the traditional tuberculin skin test (TST).
IFN-γ is encoded by the IFNG gene located on chromosome 12 in humans. The mature protein consists of 143 amino acids with a molecular weight of approximately 17 kDa. Its secretion is induced by interleukin-12 (IL-12) and interleukin-18 (IL-18) signaling pathways, and it signals through the IFN-γ receptor (IFNGR), activating the JAK-STAT1 pathway to upregulate numerous downstream immune effector genes. Accurate measurement of this cytokine provides valuable insight into Th1-type immune polarization, vaccine immunogenicity, transplant rejection risk, and autoimmune disease activity.
Testing Samples
Whole Blood
Heparinized whole blood is the standard specimen for interferon-gamma release assays (IGRAs) used in tuberculosis screening. Venous blood collected in lithium-heparin tubes is stimulated ex vivo with specific mycobacterial antigens (ESAT-6, CFP-10, and TB7.7 peptides), and the released IFN-γ in plasma is subsequently quantified. Samples should be processed within specified time windows (typically 8–16 hours at room temperature, depending on the assay system) to maintain lymphocyte viability and responsiveness.
Plasma and Serum
Plasma (collected with EDTA or heparin anticoagulants) and clotted serum samples are used for direct quantification of circulating IFN-γ levels. These matrices are applicable to systemic cytokine profiling in conditions such as hemophagocytic lymphohistiocytosis (HLH), cytokine release syndrome, chronic inflammatory disorders, and therapeutic drug monitoring following IFN-γ administration. Plasma separated after antigen stimulation is the primary readout specimen for IGRA protocols.
Peripheral Blood Mononuclear Cells (PBMCs)
Isolated PBMCs, obtained through density-gradient centrifugation (e.g., Ficoll-Paque separation), serve as the cellular substrate for ELISpot assays and intracellular cytokine staining. PBMC-based methods enable single-cell resolution analysis of IFN-γ-secreting lymphocyte frequencies and are particularly valuable in vaccine trials, immunogenicity studies, and characterization of antigen-specific T cell responses.
Cell Culture Supernatants and Biological Fluids
IFN-γ can be measured in stimulated cell culture supernatants for research on immune cell function, drug candidate screening, and cytokine profiling. Additionally, cerebrospinal fluid (CSF), bronchoalveolar lavage fluid (BALF), and pleural fluid may be tested in specific diagnostic contexts, such as confirming tuberculosis meningitis or pleuritis, where local IFN-γ production carries diagnostic significance.
Testing Items
IFN-γ determination encompasses a range of quantitative and qualitative test parameters tailored to different clinical and research objectives:
- Quantitative serum/plasma IFN-γ concentration (typically reported in pg/mL, with analytical ranges spanning 2–1000 pg/mL depending on the assay kit)
- IGRA-specific results: IFN-γ response to TB-specific antigen stimulation (ESAT-6/CFP-10 peptide cocktail), mitogen-positive control response, and nil (negative) control baseline
- Spot-forming cells (SFCs) per 10⁶ PBMCs in ELISpot assays following antigen stimulation
- Intracellular IFN-γ expression frequency by flow cytometry, reported as percentage of CD4+ or CD8+ T cells producing IFN-γ with or without stimulation
- IFN-γ induction capacity following stimulation with phytohemagglutinin (PHA), anti-CD3/CD28 antibodies, or specific peptide pools
- Simultaneous multi-cytokine panels including IFN-γ alongside IL-2, TNF-α, IL-4, and IL-17 for Th1/Th2/Th17 profiling
- Neutralizing antibody detection against therapeutic IFN-γ in patients receiving cytokine-based therapy
Testing Methods
Several validated analytical platforms exist for IFN-γ measurement, each with distinct performance characteristics, sensitivity thresholds, and throughput capabilities:
- Sandwich ELISA: The most widely used method, employing a capture antibody immobilized on microplate wells and an enzyme-conjugated detection antibody. Colorimetric signal development is quantified spectrophotometrically, with concentrations derived from standard curves. Detection limits typically reach 1–5 pg/mL. This method underpins commercial IGRA systems for tuberculosis diagnosis.
- ELISpot Assay: A highly sensitive technique for enumerating IFN-γ-secreting cells. Captured cytokine forms visible spots around individual secreting cells, with results expressed as spot-forming units. Sensitivity can reach 1 in 100,000 cells, making it the preferred method for detecting low-frequency antigen-specific T cell responses in vaccine studies.
- Flow Cytometry (Intracellular Cytokine Staining): Following stimulation with secretion inhibitors (e.g., brefeldin A), IFN-γ is retained intracellularly and detected using fluorescently labeled monoclonal antibodies. This approach permits simultaneous surface marker phenotyping and multiparametric analysis of IFN-γ-producing cell subsets.
- Chemiluminescence Immunoassay (CLIA): Offers enhanced analytical sensitivity and wider dynamic range compared to colorimetric ELISA, with automated processing on immunoassay analyzers for high-throughput clinical laboratories.
- Bioassays (Antiviral Activity): Functional assays measuring IFN-γ's ability to inhibit viral cytopathic effects in susceptible cell lines, with results expressed in international units (IU/mL) calibrated against WHO reference standards. These methods assess biological activity rather than mere immunoreactivity.
- Multiplex Bead-Based Assays: Luminex-type platforms enabling simultaneous quantification of IFN-γ with multiple other cytokines from limited sample volumes, valuable for comprehensive immune profiling studies.
Quality assurance protocols require rigorous adherence to internal quality controls, participation in external quality assessment schemes, and verification of analytical performance specifications including precision, accuracy, linearity, and reference intervals, consistent with the principles of ISO 15189 for medical laboratories.
Applications
IFN-γ testing supports diverse clinical and research applications across multiple medical disciplines:
- Tuberculosis Diagnosis: IGRAs are recommended by major public health guidelines for detecting latent tuberculosis infection in adults, particularly in BCG-vaccinated populations where the tuberculin skin test yields false positives.
- Immunodeficiency Evaluation: Assessment of cell-mediated immune function in patients with suspected primary immunodeficiencies, such as Mendelian susceptibility to mycobacterial disease (MSMD) caused by defects in the IL-12/IFN-γ axis.
- Transplant Medicine: Monitoring Th1 immune activation and infection risk (including CMV and TB reactivation) before and after solid organ or hematopoietic stem cell transplantation.
- Vaccine Development: Evaluation of T cell immunogenicity in clinical trials for vaccines targeting tuberculosis, HIV, malaria, SARS-CoV-2, and oncology indications.
- Autoimmunity and Inflammation: Investigation of Th1-skewed immune responses in conditions such as Crohn's disease, rheumatoid arthritis, aplastic anemia, and psoriasis, where IFN-γ contributes to disease pathogenesis.
- Immunotherapy and Cancer Research: Biomarker assessment for checkpoint inhibitor response, adoptive T cell therapy monitoring, and cytokine release syndrome surveillance following CAR-T cell administration.
- Infectious Disease Research: Study of host immune responses to intracellular pathogens including Leishmania, Salmonella, Listeria, and viral infections such as hepatitis B/C and dengue.
- Food Immunology and Hypersensitivity: Investigation of delayed-type hypersensitivity mechanisms and food protein-induced immune responses in research settings.
FAQ
What is the clinical significance of elevated IFN-γ levels?
Elevated IFN-γ levels generally indicate activation of cell-mediated (Th1-type) immunity. Clinically, this may reflect active intracellular infection, autoimmune inflammation, allograft rejection, hemophagocytic syndromes, or cytokine release syndrome. Interpretation should always be performed in conjunction with clinical presentation and other laboratory findings rather than as an isolated result.
How do IGRAs differ from the tuberculin skin test?
IGRAs measure IFN-γ release from patient blood cells in response to antigens (ESAT-6, CFP-10, TB7.7) that are present in M. tuberculosis but absent from BCG vaccine strains and most non-tuberculous mycobacteria. This confers higher specificity than the tuberculin skin test, requires only a single patient visit, and provides objective laboratory-based results. However, IGRAs cannot distinguish latent from active tuberculosis.
What factors can affect IFN-γ assay results?
Pre-analytical and analytical variables include sample processing delays, lymphocyte viability, immunosuppressive medications (corticosteroids, TNF inhibitors), recent infections, age-related immune senescence, and improper sample storage. Strict adherence to specimen handling requirements and inclusion of positive (mitogen) and negative (nil) controls in every assay run are essential for valid interpretation.
What are indeterminate IGRA results and how should they be managed?
Indeterminate results typically arise from either an excessive nil background (suggesting in vivo cytokine activation) or an inadequate mitogen-positive control response (suggesting lymphocyte anergy or technical issues). Management involves investigating potential causes, reviewing immunosuppressive therapy, and repeating the test, often in conjunction with alternative diagnostic modalities such as chest imaging.
Which analytical method offers the highest sensitivity for IFN-γ detection?
ELISpot provides the greatest functional sensitivity at the single-cell level, detecting frequencies as low as one IFN-γ-secreting cell per 100,000 cells. For soluble cytokine quantification, chemiluminescent immunoassays typically achieve the lowest detection limits among routine platforms, while multiplex bead arrays offer the advantage of simultaneous multi-cytokine measurement from minimal sample volumes.
How should blood samples for IFN-γ testing be transported and stored?
For IGRA whole blood specimens, samples should be held at room temperature (approximately 22°C) and stimulated within the validated incubation window specified by the assay manufacturer. For plasma or serum IFN-γ quantification, separated samples should be frozen promptly at -70°C or below to preserve cytokine integrity, avoiding repeated freeze-thaw cycles that can degrade analyte concentrations.